Ellen Lirani-Silva

Ellen Lirani-Silva

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Gait & Posture
Verified
Journal Article
Closed access
ELEllen Lirani-Silva
Ellen Lirani-Silva
RVRodrigo Vitorio
Rodrigo Vitorio
FBFabio Augusto Barbieri
Fabio Augusto Barbieri
DODiego Orcioli-Silva
Diego Orcioli-Silva
LSLucas Simieli
Lucas Simieli
LGLilian Teresa Bucken Gobbi
Lilian Teresa Bucken Gobbi

18 May 2023 in Sensors
Verified
Journal Article
Open access
PDF file
RVRodrigo Vitorio
Rodrigo Vitorio
ELEllen Lirani-Silva
Ellen Lirani-Silva
DODiego Orcioli-Silva
Diego Orcioli-Silva
VBVictor Spiandor Beretta
Victor Spiandor Beretta
AOAnderson Souza Oliveira
Anderson Souza Oliveira
VBVictor Spiandor Beretta
Victor Spiandor Beretta
The neural correlates of locomotion impairments observed in people with Parkinson’s disease (PD) are not fully understood. We investigated whether people with PD present distinct brain electrocortical activity during usual walking and the approach phase of obstacle avoidance when compared to healthy individuals. Fifteen people with PD and fourteen older adults walked overground in two conditions: usual walking and obstacle crossing. Scalp electroencephalography (EEG) was recorded using a mobile 64-channel EEG system. Independent components were clustered using a k-means clustering algorithm. Outcome measures included absolute power in several frequency bands and alpha/beta ratio. During the usual walk, people with PD presented a greater alpha/beta ratio in the left sensorimotor cortex than healthy individuals. While approaching obstacles, both groups reduced alpha and beta power in the premotor and right sensorimotor cortices (balance demand) and increased gamma power in the primary visual cortex (visual demand). Only people with PD reduced alpha power and alpha/beta ratio in the left sensorimotor cortex when approaching obstacles. These findings suggest that PD affects the cortical control of usual walking, leading to a greater proportion of low-frequency (alpha) neuronal firing in the sensorimotor cortex. Moreover, the planning for obstacle avoidance changes the electrocortical dynamics associated with increased balance and visual demands. People with PD rely on increased sensorimotor integration to modulate locomotion.

5 November 2021 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
ELEllen Lirani-Silva
Ellen Lirani-Silva
SSSamuel Stuart
Samuel Stuart
LPLucy Parrington
Lucy Parrington
KCKody Campbell
Kody Campbell
LKLaurie King
Laurie King
Background: Clinical and laboratory assessment of people with mild traumatic brain injury (mTBI) indicate impairments in eye movements. These tests are typically done in a static, seated position. Recently, the use of mobile eye-tracking systems has been proposed to quantify subtle deficits in eye movements and visual sampling during different tasks. However, the impact of mTBI on eye movements during functional tasks such as walking remains unknown.Objective: Evaluate differences in eye-tracking measures collected during gait between healthy controls (HC) and patients in the sub-acute stages of mTBI recovery and to determine if there are associations between eye-tracking measures and gait speed.Methods: Thirty-seven HC participants and 67individuals with mTBI were instructed to walk back and forth over 10-m, at a comfortable self-selected speed. A single 1-min trial was performed. Eye-tracking measures were recorded using a mobile eye-tracking system (head-mounted infra-red Tobbii Pro Glasses 2, 100 Hz, Tobii Technology Inc. VA, United States). Eye-tracking measures included saccadic (frequency, mean and peak velocity, duration and distance) and fixation measurements (frequency and duration). Gait was assessed using six inertial sensors (both feet, sternum, right wrist, lumbar vertebrae and the forehead) and gait velocity was selected as the primary outcome. General linear model was used to compare the groups and association between gait and eye-tracking outcomes were explored using partial correlations.Results: Individuals with mTBI showed significantly reduced saccade frequency (p = 0.016), duration (p = 0.028) and peak velocity (p = 0.032) compared to the HC group. No significant differences between groups were observed for the saccade distance, fixation measures and gait velocity (p > 0.05). A positive correlation was observed between saccade duration and gait velocity only for participants with mTBI (p = 0.025).Conclusion: Findings suggest impaired saccadic eye movement, but not fixations, during walking in individuals with mTBI. These findings have implications in real-world function including return to sport for athletes and return to duty for military service members. Future research should investigate whether or not saccade outcomes are influenced by the time after the trauma and rehabilitation.

24 June 2025 in Neurorehabilitation and Neural Repair
Verified
Journal Article
Open access
ELEllen Lirani-Silva
Ellen Lirani-Silva
LSLayla C. S. Silva
Layla C. S. Silva
DODiego Orcioli-Silva
Diego Orcioli-Silva
VBVictor Spiandor Beretta
Victor Spiandor Beretta
LFLucas G. S. França
Lucas G. S. França
RVRodrigo Vitorio
Rodrigo Vitorio
Background: The extent to which the cholinergic system contributes to gait impairments in Parkinson’s disease (PD) remains unclear. Electroencephalography (EEG) alpha reactivity, which refers to change in alpha power over occipital electrodes upon opening the eyes, has been suggested as a marker of cholinergic function. We compared alpha reactivity between people with PD and healthy individuals and explored its potential association with gait measures. Methods: Eyes-closed and eyes-open resting-state EEG data were recorded from 20 people with idiopathic PD and 19 healthy individuals with a 64-channel EEG system. Alpha reactivity was calculated as the relative change in alpha power (8-13 Hz) over occipital electrodes from eyes-closed to eyes-open. Gait spatiotemporal measures were obtained with an electronic walkway. Results: Alpha reactivity was reduced in people with PD compared to healthy individuals ( U = 105, P = .017); the rank-biserial correlation of .447 indicated a moderate effect size. When controlling for global cognition (Mini Mental State Examination), the group difference in alpha reactivity was no longer significant. Alpha reactivity associated with measures of gait variability only (ρ = −.437 to −.532). Conclusions: Resting-state alpha reactivity is reduced in PD, suggesting impaired cholinergic function. Reduced alpha reactivity was associated with greater gait variability, indicating a role of the cholinergic system in the mechanisms underlying gait variability. Therefore, the cholinergic system may represent a target for treatments aiming to reduce gait variability and alpha reactivity should be further explored as an endpoint for clinical trials.

1 February 2026 in Digital Health
Verified
Journal Article
Open access
WMWalter Maetzler
Walter Maetzler
SAStefan Avey
Stefan Avey
APAndrea Pilotto
Andrea Pilotto
CWC Janneke van der Woude
C Janneke van der Woude
CLChristopher A Lamb
Christopher A Lamb
WNWan-Fai Ng
Wan-Fai Ng
Background: Fatigue, impaired sleep quality and daytime sleepiness, common in neurodegenerative and immune-mediated diseases, are debilitating and have serious societal and economic implications. Currently, measurement of these symptoms largely relies on self-reported questionnaires, which are burdensome for patients and lack sensitivity, granularity and reliability. Methods: Building on a preceding feasibility study and qualification advice of the European Medicines Agency, the Clinical Observational Study of the European project Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities of daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases (IDEA-FAST) investigates the relationship between digital and clinical parameters of the target concepts of fatigue, reduced sleep quality and daytime sleepiness. Results: Between 2022 and 2025, 2000 people are being recruited at 24 European sites – 500 with Parkinson's disease, 500 with inflammatory bowel disease, 200 with each of the following diseases: Huntington's disease, rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren's syndrome and 200 healthy volunteers. Participants are followed over a 24-week period with four visits, each including a 1-week assessment phase at home using CE-certified digital health (including active and passive) technologies. The latter collect information on physical activity, physiology, cognition as well as social interaction and behaviour as core dimensions of the target concepts. Conclusion: This study will help to develop reliable, valid and efficient digital endpoints of fatigue, impaired sleep quality and daytime sleepiness for use in future clinical studies and trials.

1 January 2024
Verified
Book Chapter
Closed access
PDF file
ELEllen Lirani-Silva
Ellen Lirani-Silva
VBVictor Spiandor Beretta
Victor Spiandor Beretta
AJAlejandra Maria Franco Jimenez
Alejandra Maria Franco Jimenez
LGLilian Teresa Bucken Gobbi
Lilian Teresa Bucken Gobbi